Researchers conducted a trial a high-dose flu vaccine — IIV3-HD — with a standard-dose vaccine — IIV3-SD. A total of 31,989 participants were enrolled from 126 research centers in the United States and Canada. Around 15,991 were randomly assigned to receive IIV3-HD and 15,998 to receive IIV3-SD.
According to the study:
• Approximately 1.4 percent of participants in the high-dose group had laboratory-confirmed influenza as compared to 1.9 percent of the standard-dose group.
• At least one serious adverse event during the safety surveillance period was reported by 8.3 percent of the participants in the high-dose group as compared with nine of the participants in the standard-dose group.
• The high-dose vaccine induced significantly higher antibody responses and provided better protection against laboratory-confirmed influenza illness than the standard-dose vaccine.
More articles on quality:
Patient harms up 70% in Massachusetts hospitals
Study: 9 factors associated with SSI after colon procedures
MRSA colonization not limited to nose: Study
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.